FDA approves Pfizer's new ADHD treatment.
+ Technology/Innovation
Jamie Barrand | Dec 8, 2015

FDA approves Pfizer's new chewable ADHD treatment

With the U.S. Food and Drug Administration's (FDA) recent approval of QuilliChew ER chewable tablets, two Pfizer products are now on the market for the treatment of patients of six years and older who are living with attention deficit-hyperactivity disorder (ADHA).

“Pfizer is pleased to announce that with new QuilliChew ER, and in partnership with Tris Pharma, the developer of ER chewable tablets, we are expanding our offering of ADHD treatments to include extended-release, chewable tablet options,” Sam Azoulay, senior vice president and chief medical officer for Pfizer, said.

The approval will allow physicians to choose which medication is right for their patients.

"As a physician, it is important to have treatment choices for patients with ADHD and their caregivers," Dr. Ann Childress, president of the Center for Psychiatry and Behavioral Medicine, said. "QuilliChew ER extended-release chewable tablets give health care providers an additional treatment option to meet their patients’ needs.” 

QuilliChew ER is expected to be available in pharmacies sometime in the first quarter of 2016.

Organizations in this story

+ Pfizer

More News